Patient-derived tumoroids and proteomic signatures: tools for early drug discovery.
Anti-cancer Therapy
immuno-oncology
non-small-cell lung cancer
onco-virotherapy
patient-derived tumoroids
proteomic
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2024
2024
Historique:
received:
31
01
2024
accepted:
14
03
2024
medline:
3
5
2024
pubmed:
3
5
2024
entrez:
3
5
2024
Statut:
epublish
Résumé
Onco-virotherapy is an emergent treatment for cancer based on viral vectors. The therapeutic activity is based on two different mechanisms including tumor-specific oncolysis and immunostimulatory properties. In this study, we evaluated onco-virotherapy
Identifiants
pubmed: 38698850
doi: 10.3389/fimmu.2024.1379613
pmc: PMC11063793
doi:
Substances chimiques
Proteome
0
Biomarkers, Tumor
0
B7-H1 Antigen
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1379613Informations de copyright
Copyright © 2024 Lê, Deforges, Cutolo, Lamarque, Hua, Lindner, Jain, Balloul, Benkirane-Jessel and Quéméneur.
Déclaration de conflit d'intérêts
HL, JD, SJ, JB and EQ were employed by Transgene S.A.. PC and AL were employed by Olink. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.